Health Technology · Pharmaceuticals: Major · NSE: ACCPL · data 2026-10-09
Accretion Pharmaceuticals Ltd.
Health check: Strong (9.1/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹188.95
Market cap
₹200 cr
P/E
21.7
P/B
3.8
ROE
27.6%
ROCE
38.3%
Debt / equity
0.23
Dividend yield
0.00%
1-year return
221.9%
52-week high
₹220
52-week low
₹53.8
Operating margin
15.3%
Growth
| Revenue (last 12 months) | ₹90 cr |
| Net profit (last 12 months) | ₹10 cr |
| Sales growth, 3 years (yearly) | 45.0% |
| Profit growth, 3 years (yearly) | 353.1% |
Similar companies
Brooks Laboratories Limited (BROOKS) · Nectar Lifesciences Ltd. (NECLIFE) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS) · Bal Pharma Limited (BALPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ACCPL in NSE Scanner →